Notice of Proposed Sale · 144
Alamar Biosciences, Inc.
ALMRNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Alamar Biosciences, Inc.
- Issuer CIK
- 0002104204
- SEC file number
- 001-43235
- Phone
- 510-626-9888
- Person for whose account securities are to be sold
- Qiming Venture Partners VI, L.P.
- Relationships to issuer
- Affiliate
- Street
- 47071 BAYSIDE PARKWAY
- City
- FREMONT
- State / country code
- CA
- Postal code
- 94538
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common stock, par value $0.0001 per share | 1,558,858 | 36,664,000.00 | 69,392,766 | 10/14/2026 | Nasdaq Stock Market | J.P. Morgan Securities LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- J.P. Morgan Securities LLC
- Street
- 270 Park Avenue
- City
- New York
- State / country code
- NY
- Postal code
- 10117
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common stock | 05/27/2020 | Private investment in Series A-3 preferred shares, automatically converted into common stock upon IPO | Issuer | 2,648,607 | N | 05/26/2020 | Check |
| Common stock | 04/30/2021 | Private investment in Series A-4 preferred shares, automatically converted into common stock upon IPO | Issuer | 2,373,437 | N | 04/30/2021 | Check |
| Common stock | 08/20/2021 | Private investment in Series B preferred, automatically converted into common stock upon IPO | Issuer | 1,859,366 | N | 08/18/2021 | Check |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 10/14/2026
- Signed
- /s/ Ho Man Lam
Company context
We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics.